NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Forecast, Price & News

$19.02
-1.00 (-5.00 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.82
$19.89
50-Day Range
$18.52
$22.54
52-Week Range
$18.00
$43.26
Volume262,307 shs
Average Volume284,614 shs
Market Capitalization$954.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
30 days | 90 days | 365 days | Advanced Chart
Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Rhythm Pharmaceuticals logo

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

1099th out of 4,434 stocks

Pharmaceutical Preparations Industry

535th out of 1,734 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

Is Rhythm Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Rhythm Pharmaceuticals?

Wall Street analysts have given Rhythm Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhythm Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Rhythm Pharmaceuticals
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its earnings results on Sunday, May, 2nd. The company reported ($1.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.30 by $1.46. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $99 million.
View Rhythm Pharmaceuticals' earnings history
.

How has Rhythm Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RYTM shares have increased by 26.8% and is now trading at $19.02.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RYTM?

6 brokers have issued 12 month price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $33.00 to $67.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $50.67 in the next year. This suggests a possible upside of 166.4% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:
  • Dr. David P. Meeker, Chairman, Pres & CEO (Age 67, Pay $836.08k)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 52, Pay $692.84k)
  • Dr. Murray W. Stewart M.D., Chief Medical Officer (Age 60, Pay $744.89k)
  • Ms. Jennifer L. Chien, Exec. VP & Head of North America (Age 46, Pay $194.95k)
  • Mr. William T. Roberts, Chief Accounting Officer (Age 42)
  • Mr. Joseph Shulman, Sr. VP of Technical Operations
  • Mr. David Connolly, Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty, Sr. VP & Gen. Counsel
  • Mr. Satej Bhandarkar, Sr. VP of Program Management, Strategy & Corp. Devel.
  • Mr. Yann Mazabraud, Exec. VP & Head of International (Age 48)

What is 's approval rating as Rhythm Pharmaceuticals' CEO?

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rhythm Pharmaceuticals' key competitors?

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $19.02.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals has a market capitalization of $954.99 million. The company earns $-134,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals employs 90 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Where are Rhythm Pharmaceuticals' headquarters?

Rhythm Pharmaceuticals is headquartered at 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.